Neuropeptides
Volume 41, Issue 1 , Pages 1-24 , February 2007

On the role of prolyl oligopeptidase in health and disease

  • J.A. García-Horsman

      Affiliations

    • Centro de Investigación Príncipe Felipe, Neurobiology, Av. Autopista del Saler 16, 46013 Valencia, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 96 328 9680; fax: +34 96 321 8901.
    • ,
  • P.T. Männistö

      Affiliations

    • Department of Pharmacology and Toxicology, University of Kuopio, Finland
    • Division of Pharmacology and Toxicology, University of Helsinki, Finland
    • ,
  • J.I. Venäläinen

      Affiliations

    • Department of Pharmacology and Toxicology, University of Kuopio, Finland

Received 15 August 2006 ,Accepted 17 October 2006.

References 

  1. Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin-(1–7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 1997;30:217–221
  2. Advis JP, Krause JE, McKelvy JF. Luteinizing hormone-releasing hormone peptidase activities in discrete hypothalamic regions and anterior pituitary of the rat: apparent regulation during the prepubertal period and first estrous cycle at puberty. Endocrinology. 1982;110:1238–1245
  3. Agirregoitia N, Irazusta A, Ruiz F, Irazusta J, Gil J. Ontogeny of soluble and particulate prolyl endopeptidase activity in several areas of the rat brain and in the pituitary gland. Dev. Neurosci. 2003;25:316–323
  4. Agirregoitia N, Gil J, Ruiz F, Irazusta J, Casis L. Effect of aging on rat tissue peptidase activities. J. Gerontol. A: Biol. Sci. Med. Sci. 2003;58(9):B792–B797
  5. Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, et al. Increased gamma-aminobutyrate aminotransferase activity in brain of patients with Alzheimer’s disease. Chem. Pharm. Bull. (Tokyo). 1990;38:1748–1749
  6. Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, et al. Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer’s disease. Experientia. 1990;46:94–97
  7. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer. 2001;95:67–72
  8. Atack JR, Suman-Chauhan N, Dawson G, Kulagowski JJ. In vitro and in vivo inhibition of prolyl endopeptidase. Eur. J. Pharmacol. 1991;205:157–163
  9. Bakker AV, Jung S, Spencer RW, Vinick FJ, Faraci WS. Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal. Biochem. J. 1990;271:559–562
  10. Bar JW, Rahfeld JU, Schulz I, Gans K, Ruiz-Carrillo D, Manhart S, et al. Prolyl endopeptidase cleaves the apoptosis rescue peptide humanin and exhibits an unknown post-cysteine cleavage specificity. Adv. Exp. Med. Biol. 2006;575:103–108
  11. Barelli H, Ahmad S, Kostka P, Fox JA, Daniel EE, Vincent JP, et al. Neuropeptide-hydrolysing activities in synaptosomal fractions from dog ileum myenteric, deep muscular and submucous plexi. Their participation in neurotensin inactivation. Peptides. 1989;10:1055–1061
  12. Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, et al. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem. Biophys. Res. Commun. 1999;257:657–661
  13. Beal MF, Mazurek MF. Substance P-like immunoreactivity is reduced in Alzheimer’s disease cerebral cortex. Neurology. 1987;37:1205–1209
  14. Beal MF, Kowall NW, Mazurek MF. Neuropeptides in Alzheimer’s disease. J. Neural. Transm. 1987;(Suppl 24):163–174
  15. Bellemere G, Morain P, Vaudry H, Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J. Neurochem. 2003;84:919–929
  16. Bellemere G, Vaudry H, Mounien L, Boutelet I, Jegou S. Localization of the mRNA encoding prolyl endopeptidase in the rat brain and pituitary. J. Comp. Neurol. 2004;471:128–143
  17. Bellemere G, Vaudry H, Morain P, Jegou S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J. Neuroendocrinol. 2005;17:306–313
  18. Benzing WC, Mufson EJ, Jennes L, Armstrong DM. Reduction of neurotensin immunoreactivity in the amygdala in Alzheimer’s disease. Brain Res. 1990;537:298–302
  19. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59:411–419
  20. Berry MD, Boulton AA. Apoptosis and human neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psych. 2003;27:197–198
  21. Birney YA, O’Connor BF. Purification and characterization of a Z-pro-prolinal-insensitive Z-Gly-Pro-7-amino-4-methyl coumarin-hydrolyzing peptidase from bovine serum – a new proline-specific peptidase. Protein. Expr. Purif. 2001;22:286–298
  22. Boettger A, Kertscher U, Steinmann C, Baeger U, Siems WE, Heder G. Degradation of bradykinin in semen of ram and boar. Biochem. Pharmacol. 1993;45:1983–1988
  23. Brandt I, De Vriendt K, Devreese B, Van Beeumen J, Van Dongen W, Augustyns K, et al. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides. 2005;26:2536–2546
  24. Breen G, Harwood AJ, Gregory K, Sinclair M, Collier D, St Clair D, et al. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar. Disord. 2004;6:156–161
  25. Camargo AC, Caldo H, Emson PC. Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline-endopeptidase). Biochem. Biophys. Res. Commun. 1983;116:1151–1159
  26. Casarini DE, Boim MA, Stella RC, Schor N. Endopeptidases (kininases) are able to hydrolyze kinins in tubular fluid along the rat nephron. Am. J. Physiol. 1999;277:F66–F74
  27. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension. 2004;43:1140–1145
  28. Chappell MC, Iyer SN, Diz DI, Ferrario CM. Antihypertensive effects of angiotensin-(1–7). Braz. J. Med. Biol. Res. 1998;31:1205–1212
  29. Checler F, Emson PC, Vincent JP, Kitabgi P. Inactivation of neurotensin by rat brain synaptic membranes. Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase. J. Neurochem. 1984;43:1295–1301
  30. Checler F, Amar S, Kitabgi P, Vincent JP. Catabolism of neurotensin by neural (neuroblastoma clone N1E115) and extraneural (HT29) cell lines. Peptides. 1986;7:1071–1077
  31. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer. Metastasis. Rev. 2003;22:259–269
  32. Cheng L, Lumb M, Polgár L, Mudge AW. How can the mood stabilizer VPA limit both mania and depression?. Mol. Cell. Neurosci. 2005;29:155–161
  33. Chevallier S, Goeltz P, Thibault P, Banville D, Gagnon J. Characterization of a prolyl endopeptidase from Flavobacterium meningosepticum. Complete sequence and localization of the active-site serine. J. Biol. Chem. 1992;267:8192–8199
  34. Collins PJ, McMahon G, O’Brien P, O’Connor B. Purification, identification and characterisation of seprase from bovine serum. Int. J. Biochem. Cell. Biol. 2004;36:2320–2333
  35. Contijoch AM, Johnson AL, Advis JP. Norepinephrine-stimulated in vitro release of luteinizing hormone-releasing hormone (LHRH) from median eminence tissue is facilitated by inhibition of LHRH-degrading activity in hens. Biol. Reprod. 1990;42:222–230
  36. Cumming RC, Andon NL, Haynes PA, Park M, Fischer WH, Schubert D. Protein disulfide bond formation in the cytoplasm during oxidative stress. J. Biol. Chem. 2004;279:21749–21758
  37. Cunningham DF, O’Connor B. Identification and initial characterisation of a N-benzyloxycarbonyl-prolyl-prolinal (Z-Pro-prolinal)-insensitive 7-(N-benzyloxycarbonyl-glycyl-prolyl-amido)-4-methylcoumarin (Z-Gly-Pro-NH-Mec)-hydrolysing peptidase in bovine serum. Eur. J. Biochem. 1997;244:900–903
  38. Cunningham DF, O’Connor B. Proline specific peptidases. Biochim. Biophys. Acta. 1997;1343:160–186
  39. Dalmaz C, Netto CA, Volkmer N, Dias R, Izquierdo I. Hypothalamic proline endopeptidase activity is not changed by various behavioral procedures. Brain Res. Bull. 1986;17:137–140
  40. Dalmaz C, Netto CA, Volkmer N, Dias RD, Izquierdo I. Distribution of proline endopeptidase activity in sub-synaptosomal fractions of rat hypothalamus. Braz. J. Med. Biol. Res. 1986;19:685–690
  41. Dauch P, Masuo Y, Vincent JP, Checler F. A survey of the cerebral regionalization and ontogeny of eight exo- and endopeptidases in murines. Peptides. 1993;14:593–599
  42. Dauch P, Vincent JP, Checler F. Molecular cloning and expression of rat brain endopeptidase 3.4.24.16. J. Biol. Chem. 1995;270:27266–27271
  43. Del Bel EA, Gambarini AG, Martins AR. Neuropeptide-metabolizing peptidases in neuro-2a neuroblastoma and C6 glioma cells. J. Neurochem. 1986;47:938–944
  44. Del Bel EA, Padovan AP, Padovan GJ, Sellinger OZ, Martins AR. Enzymatic inactivation of bradykinin by rat brain neuronal perikarya. Cell. Mol. Neurobiol. 1989;9:379–400
  45. De Nanteuil G, Portevin B, Lepagnol J. Prolyl endopeptidase inhibitors: a new class of memory enhancing drugs. Drug. Future. 1998;23:167–179
  46. Dendorfer A, Vordermark D, Dominiak P. Degradation of bradykinin by bovine tracheal epithelium and isolated epithelial cells. Br. J. Pharmacol. 1997;120:121–129
  47. Diosdado B, Wapenaar MC, Franke L, Duran KJ, Goerres MJ, Hadithi M, et al. A microarray screen for novel candidate genes in coeliac disease pathogenesis. Gut. 2004;53:944–951
  48. Diosdado B, Stepniak DT, Monsuur AJ, Franke L, Wapenaar MC, Mearin ML, et al. No genetic association of the human prolyl endopeptidase gene in the Dutch celiac disease population. Am. J. Physiol. Gastrointest. Liver. Physiol. 2005;289:G495–G500
  49. Dresdner K, Barker LA, Orlowski M, Wilk S. Subcellular distribution of prolyl endopeptidase and cation-sensitive neutral endopeptidase in rabbit brain. J. Neurochem. 1982;38:1151–1154
  50. Faivre-Bauman A, Loudes C, Barret A, Tixier-Vidal A, Bauer K. Possible role of neuropeptide degrading enzymes on thyroliberin secretion in fetal hypothalamic cultures grown in serum free medium. Neuropeptides. 1986;7:125–138
  51. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1–7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515–521
  52. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function. Am. J. Physiol. Heart. Circ. Physiol. 2005;289:H2281–H2290
  53. Fruitier-Arnaudin I, Cohen M, Coitoux C, Piot JM. In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase. Peptides. 2003;24:1201–1206
  54. Fukunari A, Kato A, Sakai Y, Yoshimoto T, Ishiura S, Suzuki K, et al. Colocalization of prolyl endopeptidase and amyloid beta-peptide in brains of senescence-accelerated mouse. Neurosci. Lett. 1994;176:201–204
  55. Fülöp V, Bocskei Z, Polgár L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell. 1998;94:161–170
  56. Fülöp V, Szeltner Z, Polgár L. Catalysis of serine oligopeptidases is controlled by a gating filter mechanism. EMBO Rep. 2000;1:277–281
  57. Fülöp V, Szeltner Z, Renner V, Polgár L. Structures of prolyl oligopeptidase substrate/inhibitor complexes. Use of inhibitor binding for titration of the catalytic histidine residue. J. Biol. Chem. 2001;276:1262–1266
  58. Fuse Y, Polk DH, Lam RW, Reviczky AL, Fisher DA. Distribution and ontogeny of thyrotropin-releasing hormone degrading enzymes in rats. Am. J. Physiol. 1990;259(6 Pt 1):E787–E791
  59. Fuxreiter M, Magyar C, Juhasz T, Szeltner Z, Polgár L, Simon I. Flexibility of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. Proteins. 2005;60:504–512
  60. García-Horsman, J.A., Venäläinen, J.I., Lohi, O., Auriola, I.S., Korponay-Szabo, I.R., Kaukinen, K., Mäki, M., Männistö, P.T., 2007. Deficient Activity of Mammalian Prolyl Oligopeptidase on the Immunoactive Peptide Digestion in Coeliac Disease. Scand. J. Gastroenterol., doi:10.1080/00365520601019819.
  61. Gibson A, Edwardson J, McDermott J. Post mortem levels of some brain peptidases in Alzheimer’s disease: reduction in proline endopeptidase activity in cerebral cortex. Neurosci. Res. Commun. 1991;9:73–81
  62. Goossens F, De Meester I, Vanhoof G, Scharpe S. A sensitive method for the assay of serum prolyl endopeptidase. Eur. J. Clin. Chem. Clin. Biochem. 1992;30:235–238
  63. Goossens F, De Meester I, Vanhoof G, Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur. J. Clin. Chem. Clin. Biochem. 1996;34:17–22
  64. Goossens F, Wauters JG, Vanhoof GC, Bossuyt PJ, Schatteman KA, Loens K, et al. Subregional mapping of the human lymphocyte prolyl oligopeptidase gene (PREP) to human chromosome 6q22. Cytogenet. Cell. Genet. 1996;74:99–101
  65. Goossens F, Vanhoof G, De Meester I, Augustyns K, Borloo M, Tourwe D, et al. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors–introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design. Eur. J. Biochem. 1997;250:177–183
  66. Greene LJ, Spadaro AC, Martins AR, Perussi De Jesus WD, Camargo AC. Brain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II. Hypertension. 1982;4:178–184
  67. Grellier P, Vendeville S, Joyeau R, Bastos IM, Drobecq H, Frappier F, et al. Trypanosoma cruzi prolyl oligopeptidase Tc80 is involved in nonphagocytic mammalian cell invasion by trypomastigotes. J. Biol. Chem. 2001;276:47078–47086
  68. Griffiths EC. Clinical applications of thyrotrophin-releasing hormone. Clin. Sci. (Lond). 1987;73:449–457
  69. Groth T, Synowitz J, Malsch G, Richau K, Albrecht W, Lange KP, et al. Contact activation of plasmatic coagulation on polymeric membranes measured by the activity of kallikrein in heparinized plasma. J. Biomater Sci. Polym. Ed. 1997;8:797–807
  70. Harwood AJ. Neurodevelopment and mood stabilizers. Curr. Mol. Med. 2003;3:472–482
  71. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 2003;66:179–189
  72. Harwood VJ, Schreier HJ. Prolyl oligopeptidase from Pyrococcus furiosus. Method. Enzymol. 2001;330:445–454
  73. Harwood VJ, Denson JD, Robinson-Bidle KA, Schreier HJ. Overexpression and characterization of a prolyl endopeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. J. Bacteriol. 1997;179:3613–3618
  74. Hasenohrl RU, Souza-Silva MA, Nikolaus S, Tomaz C, Brandao ML, Schwarting RK, et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides. 2000;34:272–280
  75. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 2002;283:G996–G1003
  76. Hausch F, Halttunen T, Maki M, Khosla C. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem. Biol. 2003;10:225–231
  77. Hebb AL, Poulin JF, Roach SP, Zacharko RM, Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog. Neuropsychopharmacol. Biol. Psych. 2005;29:1225–1238
  78. Heder G, Bottger A, Siems WE, Rottmann M, Kertscher U. The enzymatic degradation of bradykinin in semen of various species. Andrologia. 1994;26:295–301
  79. Hersh LB, McKelvy JF. Enzymes involved in the degradation of thyrotropin releasing hormone (TRH) and luteinizing hormone releasing hormone (LH-RH) in bovine brain. Brain Res. 1979;168:553–564
  80. Huston JP, Hasenohrl RU. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav. Brain Res. 1995;66:117–127
  81. Ichai C, Chevallier N, Delaere P, Dournaud P, Epelbaum J, Hauw JJ, et al. Influence of region-specific alterations of neuropeptidase content on the catabolic fates of neuropeptides in Alzheimer’s disease. J. Neurochem. 1994;62:645–655
  82. Irazusta J, Silveira PF, Gil J, Varona A, Casis L. Effects of hydrosaline treatments on prolyl endopeptidase activity in rat tissues. Regul. Pept. 2001;101:141–147
  83. Irazusta J, Larrinaga G, Gonzalez-Maeso J, Gil J, Meana JJ, Casis L. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem. Int. 2002;40:337–345
  84. Ishino T, Ohtsuki S, Homma K, Natori S. cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J. Biochem. (Tokyo). 1998;123:540–545
  85. Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang DM. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol. Pharmacol. 1998;53:701–707
  86. Ishiura S, Nishikawa T, Tsukahara T, Momoi T, Ito H, Suzuki K, et al. Distribution of Alzheimer’s disease amyloid A4-generating enzymes in rat brain tissue. Neurosci. Lett. 1990;115:329–334
  87. IUBMB . Enzyme Nomenclature 1992. San Diego: International Union of Biochemistry and Molecular Biology; 1992;
  88. Jaeken J, Martens K, Francois I, Eyskens F, Lecointre C, Derua R, et al. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. Am. J. Hum. Genet. 2006;78:38–51
  89. Jarho EM, Venäläinen JI, Huuskonen J, Christiaans JA, García-Horsman JA, Forsberg MM, et al. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J. Med. Chem. 2004;47:5605–5607
  90. Jarho EM, Wallén EA, Christiaans JA, Forsberg MM, Venäläinen JI, Männistö PT, et al. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions. J. Med. Chem. 2005;48:4772–4782
  91. Jiang CH, Tsien JZ, Schultz PG, Hu Y. The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc. Natl. Acad. Sci. USA. 2001;98:1930–1934
  92. Kabashima T, Fujii M, Meng Y, Ito K, Yoshimoto T. Prolyl endopeptidase from Sphingomonas capsulata: isolation and characterization of the enzyme and nucleotide sequence of the gene. Arch. Biochem. Biophys. 1998;358:141–148
  93. Kahyaoglu A, Haghjoo K, Guo F, Jordan F, Kettner C, Felfoldi F, et al. Low barrier hydrogen bond is absent in the catalytic triads in the ground state but Is present in a transition-state complex in the prolyl oligopeptidase family of serine proteases. J. Biol. Chem. 1997;272:25547–25554
  94. Kaneko T, Wood G, Crouch WL, Desiderio DM. Substance P inactivating enzymes in human cerebrospinal fluid. Peptides. 1994;15:41–47
  95. Kaspari A, Diefenthal T, Grosche G, Schierhorn A, Demuth HU. Substrates containing phosphorylated residues adjacent to proline decrease the cleavage by proline-specific peptidases. Biochim. Biophys. Acta. 1996;1293:147–153
  96. Kato T, Nakano T, Kojima K, Nagatsu T, Sakakibara S. Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme. J. Neurochem. 1980;35:527–535
  97. Kato T, Okada M, Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol. Cell. Biochem. 1980;32:117–121
  98. Katsube N, Sunaga K, Chuang DM, Ishitani R. ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci. Lett. 1996;214:151–154
  99. Kikkawa F, Kajiyama H, Ino K, Watanabe Y, Ito M, Nomura S, et al. Possible involvement of placental peptidases that degrade gonadotropin-releasing hormone (GnRH) in the dynamic pattern of placental hCG secretion via GnRH degradation. Placenta. 2002;23:483–489
  100. Kimura A, Ohnishi J, Okimura H, Hamabata T, Takahashi T. Localization of prolyl endopeptidase mRNA in small growing follicles of porcine ovary. Mol. Reprod. Dev. 1998;50:121–127
  101. Kimura A, Yoshida I, Takagi N, Takahashi T. Structure and localization of the mouse prolyl oligopeptidase gene. J. Biol. Chem. 1999;274:24047–24053
  102. Kimura A, Matsui H, Takahashi T. Expression and localization of prolyl oligopeptidase in mouse testis and its possible involvement in sperm motility. Zool. Sci. 2002;19:93–102
  103. Knisatschek H, Bauer K. Characterization of “thyroliberin-deamidating enzyme” as a post-proline-cleaving enzyme. Partial purification and enzyme-chemical analysis of the enzyme from anterior pituitary tissue. J. Biol. Chem. 1979;254:10936–10943
  104. Koida M, Walter R. Post-proline cleaving enzyme. Purification of this endopeptidase by affinity chromatography. J. Biol. Chem. 1976;251:7593–7599
  105. Kovacs GL, De Wied D. Peptidergic modulation of learning and memory processes. Pharmacol. Rev. 1994;46:269–291
  106. Kusuhara M, Hachisuka H, Nakano S, Sasai Y. Purification and characterization of prolyl endopeptidase from rat skin. J. Dermatol. Sci. 1993;6:138–145
  107. Lawrence AC, Clark IJ, Campbell DJ. Increased angiotensin-(1–7) in hypophysial-portal plasma of conscious sheep. Neuroendocrinology. 1992;55:105–114
  108. Leprince J, Cosquer D, Bellemere G, Chatenet D, Tollemer H, Jegou S, et al. Catabolism of the octadecaneuropeptide ODN by prolyl endopeptidase: identification of an unusual cleavage site. Peptides. 2006;27:1561–1569
  109. Levesque M, Parent R, Parent A. Cellular and subcellular localization of neurokinin-1 and neurokinin-3 receptors in primate globus pallidus. Eur. J. Neurosci. 2006;23(10):2760–2772
  110. Leung D, Abbenante G, Fairlie DP. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000;43:305–341
  111. Lew RA, Tetaz TJ, Glucksman MJ, Roberts JL, Smith AI. Evidence for a two-step mechanism of gonadotropin-releasing hormone metabolism by prolyl endopeptidase and metalloendopeptidase EC 3.4.24.15 in ovine hypothalamic extracts. J. Biol. Chem. 1994;269:12626–12632
  112. Lew RA, Cowley M, Clarke IJ, Smith AI. Peptidases that degrade gonadotropin-releasing hormone: influence on LH secretion in the ewe. J. Neuroendocrinol. 1997;9:707–712
  113. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1–7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394–400
  114. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RA. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1–7) in normotensive and hypertensive rats. Hypertension. 1997;30:542–548
  115. Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA. 1999;96:14694–14699
  116. Maes M, Goossens F, Scharpe S, Meltzer HY, D’Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol. Psych. 1994;35:545–552
  117. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiat. Res. 1995;58:217–225
  118. Maes M, Goossens F, Lin A, De Meester I, Van Gastel A, Scharpe S. Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoneuroendocrinology. 1998;23:485–495
  119. Maes M, Libbrecht I, Van Hunsel F, Lin AH, Bonaccorso S, Goossens F, et al. Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol. Med. 1998;28:957–965
  120. Maes M, Lin A, Bonaccorso S, Vandoolaeghe E, Song C, Goossens F, et al. Lower activity of serum peptidases in abstinent alcohol-dependent patients. Alcohol. 1999;17:1–6
  121. Maes M, Lin AH, Bonaccorso S, Goossens F, Van Gastel A, Pioli R, et al. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J. Affect. Disord. 1999;53:27–34
  122. Maes M, Monteleone P, Bencivenga R, Goossens F, Maj M, van West D, et al. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology. 2001;26:17–26
  123. Maes M, Bosmans E, Ombelet W. In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. J. Clin. Psychiat. 2004;65:71–76
  124. Mantle D, Falkous G, Ishiura S, Blanchard PJ, Perry EK. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer’s disease, Lewy body dementia, Parkinson’s disease and Huntington’s disease. Clin. Chim. Acta. 1996;249:129–139
  125. Martens K, Derua R, Meulemans S, Waelkens E, Jaeken J, Matthijs G, et al. PREPL: a putative novel oligopeptidase propelled into the limelight. Biol. Chem. 2006;387:879–883
  126. Matsubara Y, Ono T, Tsubuki S, Irie S, Kawashima S. Transient up-regulation of a prolyl endopeptidase activity in the microsomal fraction of rat liver during postnatal development. Eur. J. Biochem. 1998;252:178–183
  127. Matysiak-Budnik T, Candalh C, Dugave C, Namane A, Cellier C, Cerf-Bensussan N, et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology. 2003;125:696–707
  128. Matysiak-Budnik T, Candalh C, Cellier C, Dugave C, Namane A, Vidal-Martinez T, et al. Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology. 2005;129:786–796
  129. Mazurek MF, Beal MF, Bird ED, Martin JB. Vasopressin in Alzheimer’s disease: a study of postmortem brain concentrations. Ann. Neurol. 1986;20:665–670
  130. Mendez M, Cruz C, Joseph-Bravo P, Wilk S, Charli JL. Evaluation of the role of prolyl endopeptidase and pyroglutamyl peptidase I in the metabolism of LHRH and TRH in brain. Neuropeptides. 1990;17:55–62
  131. Michael-Titus AT, Fernandes K, Setty H, Whelpton R. In vivo metabolism and clearance of substance P and co-expressed tachykinins in rat striatum. Neuroscience. 2002;110:277–286
  132. Mitchell BF, Chibbar R. Synthesis and metabolism of oxytocin in late gestation in human decidua. Adv. Exp. Med. Biol. 1995;395:365–380
  133. Mitchell BF, Fang X, Wong S. Metabolism of oxytocin in rat uterus and placenta in late gestation. Biol. Reprod. 1997;57:807–812
  134. Miura N, Shibata S, Watanabe S. Increase in the septal vasopressin content by prolyl endopeptidase inhibitors in rats. Neurosci. Lett. 1995;196:128–130
  135. Miura N, Shibata S, Watanabe S. Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav. Brain Res. 1997;83:213–216
  136. Mizutani S, Sumi S, Oka K, Yamada R, Kurauchi O, Taira H, et al. In vitro degradation of oxytocin by pregnancy serum, placental subcellular fractions and purified placental aminopeptidases. Exp. Clin. Endocrinol. 1985;86:310–316
  137. Mizutani S, Yokosawa H, Tomoda Y. Degradation of oxytocin by the human placenta: effect of selective inhibitors. Acta. Endocrinol. (Copenh). 1992;127:76–80
  138. Mizutani S, Safwat MA, Goto K, Tsujimoto M, Nakazato H, Itakura A, et al. Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Regul. Pept. 1995;59:371–378
  139. Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, et al. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS. Drug. Rev. 2002;8:31–52
  140. Mu X, Fu X, Sun H, Beremand PD, Thomas TL, Klein WH. A gene network downstream of transcription factor Math5 regulates retinal progenitor cell competence and ganglion cell fate. Dev. Biol. 2005;280:467–481
  141. Nemeroff CB, Kizer JS, Reynolds GP, Bissette G. Neuropeptides in Alzheimer’s disease: a postmortem study. Regul. Pept. 1989;25:123–130
  142. Odaka C, Mizuochi T, Shirasawa T, Morain P, Checler F. Murine T cells expressing high activity of prolyl endopeptidase are susceptible to activation-induced cell death. FEBS. Lett. 2002;512:163–167
  143. Ohta N, Takahashi T, Mori T, Park MK, Kawashima S, Takahashi K, et al. Hormonal modulation of prolyl endopeptidase and dipeptidyl peptidase IV activities in the mouse uterus and ovary. Acta. Endocrinol. (Copenh). 1992;127:262–266
  144. Ohtsuki S, Homma K, Kurata S, Komano H, Natori S. A prolyl endopeptidase of Sarcophaga peregrina (flesh fly): its purification and suggestion for its participation in the differentiation of the imaginal discs. J. Biochem. (Tokyo). 1994;115:449–453
  145. Ohtuski S, Homma K, Kurata S, Natori S. Nuclear localization and involvement in DNA synthesis of Sarcophaga prolyl endopeptidase. J. Biochem. (Tokyo). 1997;121:1176–1181
  146. Okazaki N, Kikuno R, Ohara R, Inamoto S, Koseki H, Hiraoka S, et al. Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries. DNA Res. 2003;10:167–180
  147. O’Leary RM, O’Connor B. Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur. J. Biochem. 1995;227:277–283
  148. O’Leary RM, Gallagher SP, O’Connor B. Purification and characterization of a novel membrane-bound form of prolyl endopeptidase from bovine brain. Int. J. Biochem. Cell. Biol. 1996;28:441–449
  149. Oliveira V, Campos M, Hemerly JP, Ferro ES, Camargo AC, Juliano MA, et al. Selective neurotensin-derived internally quenched fluorogenic substrates for neurolysin (EC 3.4.24.16): comparison with thimet oligopeptidase (EC 3.4.24.15) and neprilysin (EC 3.4.24.11). Anal. Biochem. 2001;292:257–265
  150. Orlowski M, Wilk E, Pearce S, Wilk S. Purification and properties of a prolyl endopeptidase from rabbit brain. J. Neurochem. 1979;33:461–469
  151. Parvari R, Brodyansky I, Elpeleg O, Moses S, Landau D, Hershkovitz E. A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease. Am. J. Hum. Genet. 2001;69:869–875
  152. Paula RD, Lima CV, Khosla MC, Santos RA. Angiotensin-(1–7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995;26:1154–1159
  153. Pepperell, J.R., Nemeth, G., Yamada, Y., Naftolin, F., Merino, M., 2006. Localized accumulation of angiotensin II and production of angiotensin-(1–7) in rat luteal cells, and effects on steroidogenesis. Am. J. Physiol. Endocrinol. Metab.
  154. Polgár L. pH-dependent mechanism in the catalysis of prolyl endopeptidase from pig muscle. Eur. J. Biochem. 1991;197:441–447
  155. Polgár L. Prolyl endopeptidase catalysis. A physical rather than a chemical step is rate-limiting. Biochem. J. 1992;283(Pt 3):647–648
  156. Polgár L. The prolyl oligopeptidase family. Cell. Mol. Life. Sci. 2002;59:349–362
  157. Polgár L, Patthy A. Cleavage of the Lys196-Ser197 bond of prolyl oligopeptidase: enhanced catalytic activity for one of the two active enzyme forms. Biochemistry. 1992;31:10769–10773
  158. Polgár L, Kollt E, Hollosi M. Prolyl oligopeptidase catalysis. Reactions with thiono substrates reveal substrate-induced conformational change to be the rate-limiting step. FEBS. Lett. 1993;322:227–230
  159. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1–7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br. J. Pharmacol. 1994;111:652–654
  160. Potaman VN, Alfeeva LY, Kamensky AA, Nezavibatko VN. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides. 1993;14:491–495
  161. Puttonen, K.A., Lehtonen, S., Raasmaja, A., Mannisto, P.T., 2006. A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicol. In Vitro, doi:10.1016/j.tiv.2006.07.001.
  162. Pyle GG, Paaso B, Anderson BE, Allen D, Marti T, Khosla C, et al. Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses. Clin. Gastroenterol. Hepatol. 2005;3:679–686
  163. Pyle GG, Paaso B, Anderson BE, Allen DD, Marti T, Li Q, et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin. Gastroenterol. Hepatol. 2005;3:687–694
  164. Rampon C, Jiang CH, Dong H, Tang YP, Lockhart DJ, Schultz PG, et al. Effects of environmental enrichment on gene expression in the brain. Proc. Natl. Acad. Sci. USA. 2000;97:12880–12884
  165. Rawlings ND, Polgár L, Barrett AJ. A new family of serine-type peptidases related to prolyl oligopeptidase. Biochem. J. 1991;279(Pt 3):907–908
  166. Re RN, Cook JL. The intracrine hypothesis: an update. Regul. Pept. 2006;133(1–3):1–9
  167. Rennex D, Hemmings BA, Hofsteenge J, Stone SR. cDNA cloning of porcine brain prolyl endopeptidase and identification of the active-site seryl residue. Biochemistry. 1991;30:2195–2203
  168. Robinson KA, Bartley DA, Robb FT, Schreier HJ. A gene from the hyperthermophile Pyrococcus furiosus whose deduced product is homologous to members of the prolyl oligopeptidase family of proteases. Gene. 1995;152:103–106
  169. Rosen J, Tomkinson B, Pettersson G, Zetterqvist O. A human serine endopeptidase, purified with respect to activity against a peptide with phosphoserine in the P1′ position, is apparently identical with prolyl endopeptidase. J. Biol. Chem. 1991;266:3824–3834
  170. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 2003;7:496–504
  171. Rossner S, Schulz I, Zeitschel U, Schliebs R, Bigl V, Demuth HU. Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer’s disease. Neurochem. Res. 2005;30:695–702
  172. Saito M, Hashimoto M, Kawaguchi N, Shibata H, Fukami H, Tanaka T, et al. Synthesis and inhibitory activity of acyl-peptidyl-pyrrolidine derivatives toward post-proline cleaving enzyme; a study of subsite specificity. J. Enzyme. Inhib. 1991;5:51–75
  173. Sakaguchi M, Koseki M, Wakamatsu M, Matsumura E. Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice. Eur. J. Pharmacol. 2006;530:81–87
  174. Salers P, Ouafik LH, Giraud P, Dutour A, Maltese JY, Oliver C. Evidence for pyroglutamyl peptidase I and prolyl endopeptidase activities in the rat insulinoma cell line RINm 5F: lack of relationship with TRH metabolism. Mol. Cell. Biochem. 1991;106:15–24
  175. Salers P, Ouafik LH, Giraud P, Maltese JY, Dutour A, Oliver C. Ontogeny of prolyl endopeptidase, pyroglutamyl peptidase I, TRH, and its metabolites in rat pancreas. Am. J. Physiol. 1992;262:E845–E850
  176. Santos RA, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ, et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. 1988;11:I153–I157
  177. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1–7) by human vascular endothelium. Hypertension. 1992;19:II56–II61
  178. Schneider JS, Giardiniere M, Morain P. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology. 2002;26:176–182
  179. Schonlein C, Heins J, Barth A. Purification and characterization of prolyl endopeptidase from pig brain. Biol. Chem. Hoppe. Seyler. 1990;371:1159–1164
  180. Schulz I, Gerhartz B, Neubauer A, Holloschi A, Heiser U, Hafner M, et al. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur. J. Biochem. 2002;269:5813–5820
  181. Schulz I, Zeitschel U, Rudolph T, Ruiz-Carrillo D, Rahfeld JU, Gerhartz B, et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem. 2005;94:970–979
  182. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275–2279
  183. Shan L, Marti T, Sollid LM, Gray GM, Khosla C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem. J. 2004;383:311–318
  184. Shan L, Mathews II, Khosla C. Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity. Proc. Natl. Acad. Sci. USA. 2005;102:3599–3604
  185. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 2002;277:17962–17969
  186. Shinoda M, Okamiya K, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on thyrotropin-releasing hormone-like immunoreactivity in the cerebral cortex and hippocampus of aged rats. Jpn. J. Pharmacol. 1995;69:273–276
  187. Shinoda M, Matsuo A, Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur. J. Pharmacol. 1996;305:31–38
  188. Shinoda M, Miyazaki A, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav. Brain Res. 1999;99:17–25
  189. Shirasawa Y, Osawa T, Hirashima A. Molecular cloning and characterization of prolyl endopeptidase from human T cells. J. Biochem. (Tokyo). 1994;115:724–729
  190. Shishido Y, Furushiro M, Tanabe S, Shibata S, Hashimoto S, Yokokura T. Effects of prolyl endopeptidase inhibitors and neuropeptides on delayed neuronal death in rats. Eur. J. Pharmacol. 1999;372:135–142
  191. Shishido Y, Tanaka T, Tanabe S, Furushiro M, Hashimoto S, Yokokura T, et al. ZTTA, a prolyl endopeptidase inhibitor, potentiates the arginine-vasopressin-induced incorporation of [14C]leucine in rat amygdaloid and cortical slices. Pharm. Res. 1999;16:463–465
  192. Smith AI, Tetaz T, Roberts JL, Glucksman M, Clarke IJ, Lew RA. The role of EC 3.4.24.15 in the post-secretory regulation of peptide signals. Biochimie. 1994;76:288–294
  193. Smith AI, Shrimpton CN, Norman UM, Clarke IJ, Wolfson AJ, Lew RA. Neuropeptidases regulating gonadal function. Biochem. Soc. Trans. 2000;28:430–434
  194. Soeda S, Yamakawa N, Ohyama M, Shimeno H, Nagamatsu A. An inhibitor of proline endopeptidase: purification from rat brain and characterization. Chem. Pharm. Bull. (Tokyo). 1985;33:24445–24451
  195. Soeda S, Yamakawa N, Shimeno H, Nagamatsu A. Effects of polyamines on proline endopeptidase activity in rat brain. J. Neurochem. 1986;46:1304–1307
  196. Stanziola L, Greene LJ, Santos RA. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am. J. Hypertens. 1999;12:1021–1029
  197. Szeltner Z, Renner V, Polgár L. Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family. Protein. Sci. 2000;9:353–360
  198. Szeltner Z, Rea D, Juhasz T, Renner V, Mucsi Z, Orosz G, et al. Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase. J. Biol. Chem. 2002;277:44597–44605
  199. Szeltner Z, Rea D, Juhasz T, Renner V, Fülöp V, Polgár L. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. J. Mol. Biol. 2004;340:627–637
  200. Szeltner Z, Alshafee I, Juhasz T, Parvari R, Polgár L. The PREPL A protein, a new member of the prolyl oligopeptidase family, lacking catalytic activity. Cell. Mol. Life. Sci. 2005;62:2376–2381
  201. Taylor WL, Dixon JE. Catabolism of neuropeptides by a brain proline endopeptidase. Biochem. Biophys. Res. Commun. 1980;94:9–15
  202. Taylor WL, Andrews PC, Henrikson CK, Dixon JE. New fluorogenic substrates for a rat brain proline endopeptidase. Anal. Biochem. 1980;105:58–64
  203. Terwel D, Bothmer J, Wolf E, Meng F, Jolles J. Affected enzyme activities in Alzheimer’s disease are sensitive to antemortem hypoxia. J. Neurol. Sci. 1998;161:47–56
  204. Toide K, Iwamoto Y, Fujiwara T, Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J. Pharmacol. Exp. Ther. 1995;274:1370–1378
  205. Toide K, Okamiya K, Iwamoto Y, Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem. 1995;65:234–240
  206. Toide K, Fujiwara T, Iwamoto Y, Shinoda M, Okamiya K, Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn. Schmiedebergs. Arch. Pharmacol. 1996;353:355–362
  207. Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol. Biochem. Behav. 1997;56:427–434
  208. Toide K, Shinoda M, Iwamoto Y, Fujiwara T, Okamiya K, Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer’s disease. Behav. Brain Res. 1997;83:147–151
  209. Tsukahara T, Ishiura S, Sugita H. Regulation of prolyl endopeptidase activity by the intracellular redox state. J. Biol. Chem. 1990;265:21448–21453
  210. Valdivia A, Irazusta J, Fernandez D, Mugica J, Ochoa C, Casis L. Pyroglutamyl peptidase I and prolyl endopeptidase in human semen: increased activity in necrozoospermia. Regul. Pept. 2004;122:79–84
  211. Vanhoof G, Goossens F, Hendriks L, De Meester I, Hendriks D, Vriend G, et al. Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene. 1994;149:363–366
  212. Venäläinen JI, Juvonen RO, Männistö PT. Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur. J. Biochem. 2004;271:2705–2715
  213. Venäläinen JI, García-Horsman JA, Forsberg MM, Jalkanen A, Wallén EA, Jarho EM, et al. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem. Pharmacol. 2006;71:683–692
  214. Vendite D, Dalmaz C, Netto CA, Rocha JB. Undernutrition during suckling does not change the specific or total activity of hypothalamic proline endopeptidase in adult rats. Braz. J. Med. Biol. Res. 1989;22:1475–1477
  215. Wallén EA, Christiaans JA, Forsberg MM, Venäläinen JI, Männistö PT, Gynther J. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J. Med. Chem. 2002;45:4581–4584
  216. Wallén EA, Christiaans JA, Saario SM, Forsberg MM, Venäläinen JI, Paso HM, et al. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. 2002;10:2199–2206
  217. Wallén EA, Christiaans JA, Saarinen TJ, Jarho EM, Forsberg MM, Venäläinen JI, et al. Conformationally rigid N-acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. Bioorg. Med. Chem. 2003;11:3611–3619
  218. Wallén, E.A., 2003. Design and synthesis of novel prolyl oligopeptidase inhibitors. Department of Pharmaceutical Chemistry. Kuopio, University of Kuopi.
  219. Walter R. Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species. Biochim. Biophys. Acta. 1976;422:138–158
  220. Walter R, Shlank H, Glass JD, Schwartz IL, Kerenyi TD. Leucylglycinamide released from oxytocin by human uterine enzyme. Science. 1971;173:827–829
  221. Welches WR, Santos RA, Chappell MC, Brosnihan KB, Greene LJ, Ferrario CM. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J. Hypertens. 1991;9:631–638
  222. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993;52:1461–1480
  223. de Wied D, Gaffori O, van Ree JM, de Jong W. Central target for the behavioural effects of vasopressin neuropeptides. Nature. 1984;308:276–278
  224. Wilk S. Prolyl endopeptidase. Life Sci. 1983;33:2149–2157
  225. Wilk S, Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J. Neurochem. 1983;41:69–75
  226. Wilk S, Benuck M, Orlowski M, Marks N. Degradation of luteinizing hormone-releasing hormone (LHRH) by brain prolyl endopeptidase with release of des-glycinamide LHRH and glycinamide. Neurosci. Lett. 1979;14:275–279
  227. Williams RS, Harwood AJ. Lithium therapy and signal transduction. Trends Pharmacol. Sci. 2000;21:61–64
  228. Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J. 1999;18:2734–2745
  229. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417:292–295
  230. Xie HX, Nie P, Sun BJ. Characterization of two membrane-associated protease genes obtained from screening out-membrane protein genes of Flavobacterium columnare G4. J. Fish. Dis. 2004;27:719–729
  231. Yamakawa N, Shimeno H, Soeda S, Nagamatsu A. Regulation of prolyl oligopeptidase activity in regenerating rat liver. Biochim. Biophys. Acta. 1994;1199:279–284
  232. Yamanaka C, Lebrethon MC, Vandersmissen E, Gerard A, Purnelle G, Lemaitre M, et al. Early prepubertal ontogeny of pulsatile gonadotropin-releasing hormone (GnRH) secretion: I. Inhibitory autofeedback control through prolyl endopeptidase degradation of GnRH. Endocrinology. 1999;140:4609–4615
  233. Yanagisawa T, Prasad C, Peterkofsky A. The subcellular and organ distribution and natural form of histidyl-proline diketopiperazine in rat brain determined by a specific radioimmunoassay. J. Biol. Chem. 1980;255:10290–10294
  234. Yang Z, Zhang F, Zhu L, He G. Identification of differentially expressed genes in brown planthopper Nilaparvata lugens (Hemiptera: Delphacidae) responding to host plant resistance. Bull. Entomol. Res. 2006;96:53–59
  235. Yasuda Y, Mizutani S, Kurauchi O, Kasugai M, Narita O, Tomoda Y. Induction by cortisol of aminopeptidases production from the human placenta in tissue culture. Horm. Metab. Res. 1992;24:110–114
  236. Yoshimoto T, Ogita K, Walter R, Koida M, Tsuru D. Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim. Biophys. Acta. 1979;569:184–192
  237. Yoshimoto T, Simmons WH, Kita T, Tsuru D. Post-proline cleaving enzyme from lamb brain. J. Biochem. (Tokyo). 1981;90:325–334
  238. Yoshimoto T, Tsukumo K, Takatsuka N, Tsuru D. An inhibitor for post-proline cleaving enzyme; distribution and partial purification from porcine pancreas. J. Pharmacobiodyn. 1982;5:734–740
  239. Yoshimoto T, Nishimura T, Kita T, Tsuru D. Post-proline cleaving enzyme (prolyl endopeptidase) from bovine brain. J. Biochem. (Tokyo). 1983;94:1179–1190
  240. Yoshimoto T, Kado K, Matsubara F, Koriyama N, Kaneto H, Tsura D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacobiodyn. 1987;10:730–735
  241. Yoshimoto T, Sattar AK, Hirose W, Tsuru D. Studies on prolyl endopeptidase from shakashimeji (Lyophyllum cinerascens): purification and enzymatic properties. J. Biochem. (Tokyo). 1988;104:622–627
  242. Yoshimoto T, Kanatani A, Shimoda T, Inaoka T, Kokubo T, Tsuru D. Prolyl endopeptidase from Flavobacterium meningosepticum: cloning and sequencing of the enzyme gene. J. Biochem. (Tokyo). 1991;110:873–878
  243. Yoshimoto T, Miyazaki K, Haraguchi N, Kitazono A, Kabashima T, Ito K. Cloning and expression of the cDNA encoding prolyl oligopeptidase (prolyl endopeptidase) from bovine brain. Biol. Pharm. Bull. 1997;20:1047–1050
  244. Zolfaghari R, Baker CR, Canizaro PC, Feola M, Amirgholami A, Behal FJ. Human lung post-proline endopeptidase: purification and action on vasoactive peptides. Enzyme. 1986;36:165–178

PII: S0143-4179(06)00144-2

doi: 10.1016/j.npep.2006.10.004

Neuropeptides
Volume 41, Issue 1 , Pages 1-24 , February 2007

Article Tools

* Image Usage & Resolution